key: cord-0035640-u5r5bx6s
authors: Opal, Steven M.
title: Severe Sepsis and Septic Shock
date: 2008
journal: Surgery
DOI: 10.1007/978-0-387-68113-9_15
sha: 041419d6da77bbccdb271f3ac7074e5d04d76ff4
doc_id: 35640
cord_uid: u5r5bx6s

This chapter reviews the remarkable recent advances in the understanding of the molecular basis that underlies the pathophysiology of sepsis. This knowledge has improved diagnostic techniques and introduced new therapeutic agents into the standard management of patients with severe sepsis/septic shock. The current treatment regimens for sepsis are discussed, and the evidence to support each major treatment strategy is outlined in detail. Research priorities to further the optimal management of septic shock in the future are highlighted.

The terminology used to describe the septic process is, by necessity, imprecise and lacking in analytical clarity since there is no single, universally accepted, diagnostic or confirmatory test for sepsis. This has plagued the field of sepsis research as the majority of intensive care specialists in a recent survey' felt that the current definitions are inadequate and frequently miss the correct diagnosis. The loosely applied term sepsis is used to connote a syndrome when a patient develops a deleterious systemic host response to an infectious process. In its early stages, sepsis can be difficult to distinguish from an appropriate and localized inflammatory reaction to an uncomplicated infection . The innate im mune response and coagulation networks evolved to defend the host from blood loss and generalized infection following minor injury. These same inflammatory and clotting systems can be detrimental when they become excessive or dysfunctional , as they often become following ma jor injury or systemic infection.

The clinical syndrome of sepsis becomes more readily recognizable and distinguishable for controlled inflammation when overt signs of systemic inflammatory responses, tissue hypoperfusion, and organ dysfunction develop. According to current consensus definitions/ sepsis accompanied by objective signs of organ dysfunction is classified as severe sepsis. It is often apparent only in retrospect that the patient was "becoming septic," and that subtle, telltale signs were progressing to a potentially devastating pathologic state such as severe sepsis . Septic shock is defined as sepsis complicated by organ dysfunction and systemic hypotension refractory to an adequate fluid challenge. These definitions are independent of the nature of the infecting microorganism, and th ey correctly acknowledge the central role of the host inflammatory and coagulation response rather than microbial factors in the pathogenesis of sepsis. A brief summary of the recommended terminology of sepsis definitions is listed in 

Sepsis, and the associated multiorgan failure that often accompanies this systemic inflammatory process, remains a leading cause of mortality in the intensive care units (IeUs) worldwide.' It is currently estimated that as many as 700,000 patients develop severe sepsis each year in the United States.v" with similar incidence rates in several European countries.Y The incidence of severe sepsis/septic shock has continuously increased over the past three decades, and the occurrence of sepsis likely will further increase over the next several decades as the population of elderly and vulnerable patients continues to expand. The mortality rate for fully developed septic shock rema ins between 35 % and 45% despite recent improvements in treatment options and outcome.V" The outcome in sepsis is highly variable and dependent on a large number of preexisting and physiological elements, nonetheless, it is clear that this process alone accounts for hundreds of thousands of deaths per year. 4 ,5 The incidence of sepsis is increasing for several reasons, but primary among them is the fact that sepsis largely has become a disease of medical progress. While sepsis certainly Bacteremia or fungemia is not necessary or sufficient for the diagnosis of sepsis. Microorganisms may transit the bloodstream briefly and without clinical consequences; fatal septic shock may occur in the absence of documented bacteremia or fungemia. Infection (local or systemic) accompanied by a systemic inflammatory response (e.g., fever, leukocytosis, tachycardia, tachypnea). It may be difficult to distinguish a physiologic host response to infection from a deleterious (septic) response. Sepsis-induced organ dysfunction (central nervous system dysfunction, acute lung injury, renal failure, hepatic dysfunction, coagulopathy, metabolic acidosis, cardiovascular dysfunction) remote from the site of active infection; this should be distinguished from preexisting organ dysfunction. This is clinically defined as failure to maintain a systolic blood pressure above 90mmHg (or mean arterial pressure >65mmHg) following an adequate fluid challenge (>40ml/kg over 6h). occurs in previously healthy persons (e.g., meningococcal sepsis, toxic shock syndrome, and severe community-acquired pneumonia), the majority of septic patients have significant underlying diseases that place them at risk for sepsis.'? Successful management of a variety of severe trauma situations and medical illnesses and advances in surgical interventions are salvaging patients who only a few generations ago would have rapidly succumbed. This has produced a large susceptible population of patients with prolonged critical illness and impaired host defenses." These patients have a greatly increased risk of developing sepsis. Innovations in organ transplantation, implanted prosthetic devices, and long-term vascular access devices continue to expand in this patient population. The gradual aging of the population in many developed countries and the increasing prevalence of antibiotic-resistant microbial pathogens also conspire to increase the incidence of severe sepsis/septic shock.

In a study by Martin et al., over 10 million cases of sepsis from the National Hospital Discharge Survey were reviewed over a 21-year time period throughout the United States." They found that the incidence of sepsis increased by an average of 8.70/0 per year from 1979 to 2000, from 82.7 to 240/100,000 population. Sepsis was consistently and significantly more common in men than women and more common in nonwhite populations compared to white populations. The mean age of patients with severe sepsis was 60 years," but the incidence of sepsis by age was heavily splayed to the extremes of age, with a small peak in the neonatal period and a marked and progressive rise in sepsis in the elderly after age 65. 4 Gram-positive bacterial pathogens now outnumber gramnegative pathogens as a cause of sepsis, and the incidence of fungal sepsis has increased by over 200% in the past two decades. While the incidence has progressively increased, the overall crude mortality rate has steadily decreased to less than 18% from 27.9% average 20 years earlier." Similar findings have been reported in a large French study, with significant improvements in management outcomes from sepsis noted over the past decade."

The human resource losses attributable to sepsis for affected patients, family members, and society in terms of years of life lost, long-term disability, and diminished qualityof-life indices are enormous and incalculable. Recent evidence indicates that the long-term disability suffered by survivors of sepsis and other critical illnesses is considerable." The financial implications in health care expenditures for the management of sepsis are daunting as well. Each episode of severe sepsis extends the average hospital length of stay by 11 additional days and costs approximately $40,000/ episode. The added costs accrued from sepsis that develops in patients while hospitalized for other medical or surgical indications may be even higher. 13 Angus and colleagues estimated that expenditures in the United States for sepsis alone account for an incremental annual cost of nearly $17 billion."

Severe sepsis and septic shock usually arise in an unexpected fashion in patients who have another primary illness," and the severity of the underlying illness is a principal determinant of the mortality rate attributable to sepsis. This relationship was first noted by Jackson and McCabe several decades ago," and it remains true today despite numerous advances and innovations in supportive care and in medical and surgical management.IS The source of the septic focus has repeatedly been shown to have a major impact on the risk of adverse outcome from sepsis. Catheter-related sepsis and urinary tract infections have the most favorable prognosis, while intraabdominal sites of sepsis and pulmonary sources of sepsis are associated with the worst outcome.P-"

The risk of disseminated infection and sepsis following the onset of tissue invasion by pathogens from an initial site of injury varies markedly depending on the type of infection, location and degree of tissue invasion, and the intrinsic vim-lence of the causative pathogen. The likelihood of developing multiorgan dysfunction, hemodynamic compromise, and lethal septic shock after infection begins is heavily dependent on the antimicrobial defense capacity and fundamental nature of the individual host response to the microbial challenge. Many hereditary and acquired factors contribute to the risk of severe sepsis following similar types of microbial challenge. While it is widely appreciated that the elderly patient," the neutropenic patient," and the asplenic patient" all have readily measurable differences in outcome when compared with the same type of systemic infection in an otherwise healthy young adult, it is increasingly apparent that much of the mortality risk from sepsis is actually determined by our genomic background."

An expanding array of polymorphisms in immune response and regulatory genes are known to potentially affect the risk of sepsis and its outcome.P:" A major research priority in clinical research at present is the development of an information system that can rapidly and correctly identify and balance the influence of all the relevant genes and gene products that ultimately determine the fate of patients with systemic inflammatory states. The magnitude, dynamics, and complexity of interacting networks that contribute to acute inflammatory states such as sepsis indicate that deciphering this process in real-time patient care settings will be a challenge indeed. An entirely different conceptual framework on which to formulate a greater understanding of sepsis pathophysiology may be required to adequately integrate this information.

An initial attempt at accomplishing the goal of reanalyzing sepsis in the genomic era has been proposed as the PIRO system," which stands for predisposing factors, infection, response, and organ dysfunction. This classification system is depicted in Table 15 .2 and is fashioned after the TNM (tumor, nodes, metastases) system in codifying malignant diseases. It is predicated on the hypothesis that breaking down sepsis into its component parts (the reductionist approach to complexity) will lead to an improved understanding of the mechanisms that underlie sepsis itself. Intuitively, a classification scheme that adequately separates a number of important and easily recognizable subgroups of patients with very different risk factors for the development of sepsis, and risk of death from sepsis, is an appealing strategy in better understanding sepsis in general.

The microbiology of sepsis (or the I in the PIRO system) has changed over the past 50 years from what was once a primarily gram-negative bacterial infection in the 1950s through the 1980s (previously termed gram-negative sepsis or endotoxic shock) to what is now principally a gram-positive bacterial process.' The ubiquitous use of vascular catheters, other implantable devices, progressive antibiotic resistance among gram-positive bacteria, and improved antimicrobial agents against gram-negative bacterial pathogens have all contributed to the progressive emergence of gram-positive bacterial pathogens as the major causative microorganisms of sepsis by the beginning of the 21st century."

Fungal organisms are increasingly recognized as impor- microorganisms may also account for some cases of "culturenegative" sepsis."

Bacterial endotoxin, which is composed of lipopolysaccharide (LPS), is an intrinsic component of the outer membrane of gram-negative bacteria and is essential for the viability of enteric bacteria." An endotoxin-deficient strain of Neisseria meningitidis has been isolated that is viable and is 10-to 100fold less potent an inducer of cytokine production than wildtype bacteria." Lipopolysaccharide is a phosphorylated, polar macromolecule that contains hydrophobic elements in the fatty acids of its lipid A core structure and hydrophilic elements in its repeating polysaccharide surface components.

Humans are one of the most susceptible species to the profound immunostimulant properties of endotoxin, which may be lethal following intravenous challenge in minute doses. Whether endotoxin is released into the human circulatory system in its free form (released from dead organisms or shed from the membrane sf viable organisms as microparticles) or bound to the cell wall of intact bacteria, an intense systemic inflammatory response results. Endotoxin in the prototypic pathogen-associated molecular pattern (PAMP) that functions to alert the host's innate immune defenses to the presence of invading gram-negative bacteria." It is the host response to the systemic release of endotoxin (or other PAMPs), rather than the endotoxin itself, that accounts for its potentially lethal consequences.'

In human plasma, endotoxin immediately comes in contact with endotoxin-binding proteins, the most important of which is LPS-binding protein (LBP).39 This protein facilitates the transfer of LPS to the surface of immune effector cells expressing the anchoring receptor molecule CDI4. 40 Another endogenous LBPin plasma is bactericidal permeability-increasing protein (BPI),41 which is principally expressed on neutrophil membranes and primary granules. Bactericidal permeability-increasing protein binds with high affinity to LPS and is a potent inhibitor of endotoxin activity. The concentration of LBP in the plasma is two to three orders of magnitude higher than that of BPI, and therefore, most of the LPS released in the plasma binds to LBP and is efficiently carried to myeloid cells in its active form. The BPI functions as an endogenous antiendotoxin molecule, and systemic infusions of high levels of BPI may become a treatment strategy for endotoxin-induced injury."

The long-sought-after primary cellular receptor for endotoxin on immune cells has been identified.P" The Toll-like receptors (TLRs) are type 1 transmembrane receptors and are now known to be the receptors for multiple microbial structures such as endotoxin, peptidoglycan, bacteriallipopeptides, viral and bacterial nucleic acids, flagella, and lipoteichoic acid. The TLRs belong to a network of pattern recognition receptors of the innate immune system that alert effectors cells to the presence of a microbial pathogen." This system includes up to 11 TLRs, CD14, and components of the alternate complement system and mannose-binding lectin system ( Forms heterodimers with TLR2 for bacteriallipopeptide, outer surface proteins of Borrelia spp., and possibly other microbial ligands Bacterial and Mycoplasma lipopeptide, ? peptidoglycan; lipoarabinomannan from Mycobacteria, lipoteichoic acid, fungal cell wall components, LPS of spirochetes Double-stranded viral RNA probably signals from inside endosomal vacuoles LPS, respiratory syncytial virus proteins, HSP60, fibrinogen, heparan sulfate Flagellin from gram-positive or gram-negative bacteria Forms heterodimers with TLR2 in recognition of Mycoplasma lipopeptides and fungal elements (zymosan) Binds to single-strand (ss) RNA in mice (? humans); binds to antiviral compounds, imidazoquinolines" Recognizes ssRNA in humans inside intracellular endosomes, binds imidazoquinolines" Unmethylated CpG motifs in microbial DNA; signaling occurs inside endosomal vacuoles Unknown, may interact with TLR2 to form heterodimers Recognizes uropathogenic bacteria in the urogenital tract in mice (? humans) 48 Recognizes LPS, peptidoglycan, lipoarabinomannan, fungal antigens; binds with TLRs for cell signaling Pathogen-associated molecular patterns that are exposed to the C3 thioester bond" Recognizes mannosides expressed on bacterial, fungal, viral surfaces and activates C4 and C2 s0 C', complement; HSP, heat-shock protein; LPS, lipopolysaccharide; MBL, mannose-binding lectin; TLR, Toll-like receptor. Source: Adapted from Cristofaro and Opal,46 by permission of Expert Opinion on Therapeutic Targets.

The principal endotoxin transmembrane receptor is TLR4. 43 It functions along with an extracellular adaptor protein known as MD2 and a critically important pattem recognition receptor CD14 that anchors microbial antigens to the surface of myeloid cells . 39 ,5 l These surface receptor molecules aggregate on membrane regions known as lipid rafts where the intracellular signaling process begins . The precise mechanisms by which TLR4 activates gene transcription of cytokines, acute-phase proteins, coagulation, and nitric oxide synthase (NOS) are known in considerable detail (Fig, 15. 1),46 although other regulatory and accessory pathways of gene induction and control have not yet been fully characterized." A well-characterized series of tyrosine and theoninefserine kinases is activated by TLR4 engagement with LPS, and this intracellular signaling leads to phosphorylation of IKB (inhibitor of nuclear factor kappa B [NF-KB]). This releases the transcriptional activator NFKB from the cytoplasm and allows it to translocate into the nucleus. The NFKB and a number of other of transcriptional activators are transferred to the nucleus, where hundreds of genes are activated or suppressed in response to the presence of endotoxin.P:" Details of these events and interactions are important as they form the molecular basis for novel therapeutic agents to treat sepsis .

The receptor TLR2 recognizes a large number of bacterial, fungal, mycobacterial, and mycoplasma surface structures in heterodimeric combination with either TLRI or TLR6. 54 Toll -like receptor 9 is the cellular receptor for unmethylated CpG motifs found in bacterial DNA, 55 while TLR3 recognizes double-strain viral RNA,56 and TLR8 detects single-strand RNA. 47 Also, TLR5 recognizes bacterial flagellin found on motile gram-positive and gram-negative bacteria. 57 The TLRs belong to the pattern recognition molecules' innate immune system and initiate this rather nonspecific, antimicrobial defense system. It lacks the precision of the highly specific and clonal acquired immune system (B cells and T cells I, yet its rapid reaction time in phagocytosis and clearance of pathogens in the early phases of microbial invasion makes the innate immune response a critical host defense mechanism. Excessive activation and disordered regulation of the innate immune system and its cellular components (neutrophils, monocytes, macrophages, natural killer INK] cells) are primarily responsible for the pathogenesis of early septic shock. 23, 38 Elements of the acquired immune system and defects in adaptive immunity may playa pivotal role in toxic shock syndromes" and in the later stages of sepsis (the late immune-suppressive phase of sepsis]."

Another important microbial mediator in some forms of septic shock from gram-positive bacterial pathogens is bacterial superantigen. Superantigens are a unique group of microbially derived protein antigens found in some streptococci, growth factor-associated kinase-I, JNK, Janus N-terminal-linked kinase; MAPK, mitogen-activat ed protein kinase; IRF3, int erferon regulatory factor; IFN, interferon; IP-lO, interferon-inducible protein-10; IKK, I1cB kinase; NEMO (another name for IKK-NFlCB essential modulator); IlCB, inh ibitory subunit lCB; NFlCB, nuclear factor 1CB; MHC, major histocompatibility complex; NOS, nitric oxide synthase; TH 1 , type 1 thymic-derived CD4+ lymphocyte helper cells.

Opinion on Therapeutic Targets .] staph ylococci, and perhaps other pathogens; each possesses an unusual immunologic property. These superantigens have the capacity to rapidly activate large numbers of CD4+T cells by circumventing the conventional antigen-processing and presentation system of adaptive immunity."

Conventional protein antigens are internalized by antigen-presenting cells (APCs) and undergo limited proteolysis. They are then processed within the endosomal component of macrophages or dendritic cells . Appropriate size peptide sequences of these antigens [epitopes] are then processed and inserted into the central groove of major histocompatibility (MHC) class IT molecules on the membrane surface of APCs . Specific, clonotypic CD4+T cells that recognize each unique epitope are then activated. Clonal expansion of this small subset of T cells results in a physiologic immune response to the neoantigen/" Superantigens, by contrast, do not undergo processing by APCs and bind directly to class II molecules outside the epitope-specific peptide groove on APCs . Superantigens then bind to the V~region of the T-cell receptor (TCR) on CD4+ T cells. This binding brings CD4+ T cells, and APC forms a bridge that then activates both the APC and T-cell populations expressing the appropriate V~region of the TCR . Conventional peptide antigens specifically stimulate about I in 10 5 circulating lymphocytes that can recognize its unique epitope. Superantigens such as the toxic shock syndrome toxin-I from Staphylococcus aureus binds to the V~2 region of T cells that is found in up to 10%-20% of human lymphocyte populations." This activates large numbers of both lymphocytes and macrophages, and the synthesis and release of proinflammatory cytokines proceeds in an uncontrolled fashion. Staphylococcal and streptococcal strains can produce a variety of different superantigenic exotoxins capable of widespread immune activation if introduced into the circulation. 58 ,6O,61 Superantigen-induced immune activation may terminate in a form of septic shock known as toxic shock syndrome if the source of the superantigen is not expeditiously removed. Polymicrobial infections that release both bacterial superantigens and endotoxin may be particularly injurious to the host. The systemic toxicity of bacterial endotoxin is magnified by immune activation by superantigens that prime the immune system to overreact to endotoxin signaling ( Fig. 15.2) . 62 Peptidoglycan from the cell wall of bacteria, capsular antigens, lipoteichoic acid, lipopeptides, microbial DNA, viral RNA, fungal elements, microbial toxins, and pro coagulant substances produced by microbial pathogens may all contribute to the pat hogenesis of sepsis. Peptidoglycan and lipopeptides from gram -positive bacteria interact with CDI4 molecules and activate inflammatory cells via TLR2 in a manner comparable to that observed by bacterial endotoxin." Moreover, gram -positive bacterial and fungal pathogens may induce hypotension with redistribution of blood flow and splanchnic vasoconstriction. The ischemia and reperfusion of blood vessels that supply the mucosal surfaces of the gastrointestinal (GI) tract may disrupt the permeability barrier to bacterial products. Translocation of microbial antigens, including bacterial endotoxin, may occur during periods of hypoperfusion of the GI rnucosa.f This injurious process has prompted interest in efforts to boost the GI mucosal barrier through immunonutrition, epithelial growth factors, and selective decontamination of the GI tract in critical illness. Proinflammatory cytokines playa pivotal role in the pathogenesis of sepsis. In animal studies, the administration of human tumor necrosis factor-a (TNF-a), an endogenous monocyte-macrophage-derived protein, is potentially lethal." and pronounced hemodynamic, metabolic, and hematologic changes occurred when TNF-a was administered to human volunteers." Hypotension induced by even minute amounts of interleukin-Iu (IL-la) when given as an infusion to humans is a graphic demonstration of the pathologic potential of proinflammatory cytokines."

The major proinflammatory cytokines, TNF-a and IL-l~, function in concert with an expanding group of host-derived proinflammatory mediators and an equally impressive array of antiinflammatory mediators that work in a coordinated fashion to produce the systemic inflammatory response (see Table 15 .4). Cytokines and chemokines function as a network of communication signals among neutrophils, monocytes, macrophages, lymphocytes, and endothelial cells. Autocrine and paracrine activation amplifies cytokine signaling of the inflammatory response within the microenvironment once it is activated by a systemic microbial challenge (e.g., endotoxemia). Much of the proinflammatory response is compartmentalized within the proximal region of initial injury (e.g., lung tissue or peritoneum). If local control is not achieved, then the inflammatory response spills over into the systemic circulation, resulting in a generalized reaction with endothelial injury, coagulation activation, and remote organ injury. The endocrine-like effects of the circulating cytokines and chemokines maintain the generalized inflammatory process that typifies the septic state. 67 ,68 Reactive oxygen and nitrogen species Granulocyte-macrophage colony-stimulating factor Macrophage migration inhibitory factor Upregulation of receptors:

TLR4, TLR2, CDI4 Coagulation factors:

Thrombin, factor Xa, tissue factor: FVIIa, fibrinogen, heparan sulfate, uPAR High-mobility group box-I The proinflammatory mediators are activated in the early phases of sepsis (the first 12 to 24h) and are rapidly countered by the endogenous antiinflammatory components of the systemic immune response. Cytokine antagonists, decoy receptors, soluble receptors, antiinflammatory cytokines, and downregulation of tissue receptors prevail in the later phases of sepsis." Mice deficient in T cells and B cells respond to endotoxin challenge in the same manner as normal mice." indicating that neutrophils and monocyte-macrophage generated cytokines are sufficient to induce the early septic process. Lymphocyte activity and their cytokines and interferons become important in the regulation of later phases of sepsis and may ultimately determine the outcome in septic shock.

Important functional differences exist within CD4+ T cells.

Activated, yet uncommitted, CD4+ T cells (THo cells) have two major pathways of functional differentiation. The T cells exposed to IL-12 in the presence of IL-2 are driven toward a TH1-type functional development. These cells produce large quantities of interferon-y(IFN-y),TNF-a, and IL-2and promote a proinflammatory, cell-mediated immune response. Uncommitted CD4+T cells exposed to IL-4will preferentially develop into a THrtype phenotype; TH 2 cells secrete IL-4, IL-lO, and IL-13. These cytokines promote humoral immune responses and attenuate macrophage and neutrophil activity."

The TH1-type cytokines suppress the expression of TH 2type cytokines. Interferon-y inhibits the synthesis of IL-lO; conversely, the TH 2-cell-derived cytokine IL-lO is a potent inhibitor of TNF-a and IFN-y synthesis by TH 1 cells. The nature of the initial lymphocyte response is critical because the system tends to polarize over time into either a TH 2 - Tl-L-type response." Functional differentiation of CDS cells has also been detected (CDS+ type 1 and type 2 cells]." Cytotoxic T cells can induce apoptosis by surface expression of Fas ligand, which fixes to cell membrane Fas on target cells and via the release of perforins and granzymes. Regulation of T-cell activity in sepsis is clinically relevant. A generalized TH 2-type response characteristically occurs after an initial septic insult. The stress hormone response in septic shock, with expression of adrenocorticotropic hormone, corticosteroids, prostaglandins, and catecholamines, promotes a TH 2 response after systemic injury. Hotchkiss et a1. 59,72 have provided another potential explanation for the relative immune suppression (or immune paralysis) that often accompanies sepsis. Selective apoptosis of CD4+ T cells and B cells along with follicular dendritic cells is highly characteristic of severe sepsis. This selective loss of immune effector cells may contribute to the increased risk for secondary bacterial or fungal infection in the later phases of sepsis. Neutrophils are naturally apoptotic cells, and inflammatory cytokines and growth factors actually cause delayed apoptosis of neutrophils in sepsis." Accelerated caspase function and excess apoptosis also occur in intestinal epithelial cells, compromising mucosal permeability barrier function of the gut. 59 This pathophysiologic state is further aggravated by sepsis-induced endotoxin tolerance (or reprogramming]" and deactivation of monocytes, macrophages, and neutrophils by cytokine inhibitors such as IL-l receptor antagonist and antiinflammatory cytokines such as IL-I0. 75 Depressed expression of MHC class II antigens (HLA-DR), TNF receptors, TLRs, and perhaps other cell surface activation signals may contribute to this functionally immunosuppressed state."

Nitric oxide (NO) is a freely diffusible gas and highly reactive free radical with a short half-life (1-3s).76 It has an essential role in the pathophysiology of septic shock. Nitric oxide is generated by one of three isoforms of NOS (endothelial, neuronal, and inducible NOS).77 Regulation of the human NOSs is complex. Full expression of the inducible form of NOS requires TNF-a, IL-l, LPS, and probably other regulatory elements. Nitric oxide is the major endothelial-derived relaxing factor that initiates the systemic hypotension observed in septic shock. Nitric oxide activates guanylate cyclase, which increases cyclic guanosine monophosphate levels inside vascular smooth muscle cells. The resultant smooth muscle relaxation in precapillary arterioles lowers peripheral vascular resistance. 76 The other major physiologic effects of NO in septic shock are increased intracellular killing and regulation of platelet and neutrophil adherence. In the presence of reactive oxygen intermediates such as superoxide anion, NO leads to the formation of peroxynitrite. Peroxynitrite decays intracellularly into highly cytotoxic molecules, including hydroxyl radicals and nitrosyl chloride. These reactive nitrogen intermediates (RNI) activate an intracellular enzyme known as PARP (poly ADP-ribose polymerase). This enzyme rapidly depletes the cellular contents of adenosine triphosphate (ATP), resulting in cellular energy starvation." These RNIs also induce lipid peroxidation and cause loss of cell viability." Nitric oxide also inhibits a variety of metalloenzymes and essential enzymes in the tricarboxylic acid cycle, the glycolytic pathway, DNA repair systems, and electron transport pathways.

As with many other elements of the host inflammatory response, NO may have both advantageous and disadvantageous properties in sepsis. Nitric oxide regulates microcirculation to vital organs and contributes to intracellular killing of microbial pathogens. Excess and prolonged release of NO, however, results in systemic hypotension and contributes to septic shock. Regulation of NO synthesis remains an experimental target in the treatment of sepsis, but preservation of the favorable attributes of NO in the microcirculation while limiting its toxic effects remains a major therapeutic challenge.77

Activation of the coagulation system, generation of a consumptive coagulopathy, systemic fibrinolysis, and diffuse microthrombi are potentially life-threatening complications of severe sepsis." The innate immune system and the coagulation system coevolved as early defense systems against microbial invasion and tissue injury and remain highly integrated and coregulated. The tissue factor pathway (formerly known as the extrinsic pathway) is the principal mechanism by which the coagulation system is activated in human sepsis." The contact factors (also known as the intrinsic pathway) play an accessory role as amplifiers of clotting once thrombin is generated (Fig. 15.3) . Intravascular fibrin deposition impairs blood flow, promotes neutrophil and platelet adherence, and may contribute to at least some forms of multiorgan failure in sepsis." Depletion of coagulation factors and activation of plasmin, antithrombin, and activated protein C may result in a hemorrhagic diathesis in some septic patients. Depletion of endogenous anticoagulants and impaired fibrinolysis may generate a procoagulant state and portend a poor prognosis." Inflammatory signals generated by intravascular thrombin generation and fibrin deposition contribute to microvascular injury as neutrophils and monocytes are drawn into areas of clot formation. Specialized receptors known as the protease-activated receptors (PAR 1-4) recognize thrombin, tissue factor:factor VII complex, factor X, and activated protein C. 83 These receptors are present on endothelial surfaces, neutrophils, and platelets and initiate the release of inflammatory cytokines, chemokines, platelet-activating factor, and P-selectin, among other mediators. The clotting system works in concert with the inflammatory networks in an attempt to localize the site of injury or infection from the rest of the host tissues. Extensive injury or failure of the early local control mechanism leads to generalized coagulation activation, inflammation, and the pathologic process of severe sepsis and septic shock."

Clinical trials with recombinant tissue factor pathway inhibitor," activated protein C,86 and plasma-derived antithrombin" for treatment of sepsis resulted in disappointing results except for recombinant human activated protein C (drotrecogin alfa activated). This treatment strategy yielded a statistically significant survival benefit in a multicenter clinical trial with 1690 patients. The 2S-day all-cause mortality in the recombinant human activated protein C group was 24.7%, while the mortality rate in the placebo group was . The precise mechanism of action of recombinant human activated protein C that accounts for its beneficial effects is not entirely clear, but it is not likely to be its direct anticoagulant activity." Heparin alone and other anticoagulants such as hirudin have not been shown to improve outcome in clinical settings or experimental models of sepsis,89,90and all of these endogenous anticoagulants have antiinflammatory properties." Activated protein C also has profibrinolytic activity and antiapoptotic activities on endothelial cells in experimental systems." which may spare the endothelial surface for the injurious effects of systemic inflammation and disordered coagulation.i' :" Clinical investigations with antithrombin, tissue factor pathway inhibitor, and other coagulation inhibitors continue as possible treatment regimens for specific subgroups of septic patients.

The recruitment of neutrophils, platelets, and other inflammatory cells to an area of localized infection or clot formation is an essential component of the host innate immune response . Localization and eradication of invasive microorganisms at the initial site of injury is the primary defense strategy against microbial pathogens. Th is physiologic process may become deleterious if diffuse neutrophil-endothelial cell interactions occur throughout the circulation in response to systemic inflammation.w" :" The mechanisms responsible for the migration of neutrophils from the intravascular space into the interstitium, where invasive microorganisms are found, are depicted in Figure 15 It has been discovered that several host-derived mediators may contribute to the pathogenesis of septic shock. Macrophage migration inhibitory factor (MIF) is a late mediator induced by glucocorticoid excess; it has many proinflammatory actions on effector cells, including the capacity to upregulate TLR4 expression," impair myocardial function," delay neutrophil apoptosis," and contribute to lethal septic shock." Inhibitors of MIF may have a potential therapeutic role in human sepsis. 93,96

High-mobility group box-l (HMGB-l) protein is a lateacting cytokine-like DNA-binding protein that appears to contribute to late-onset inflammatory activities in septic shock.":" Inhibitors of HMGB-l demonstrate some therapeutic benefit in experimental sepsis." Complement components, particularly the chemoattractant factor C5a,l00 and loss of the regulatory element Cl esterase inhibitor" can produce vasodilatation and may participate in the pathogenesis of septic shock. The triggering receptor expressed on myeloid cells TREM-I 101 and NODI/NOD2 (nucleotide-binding oligomerization domain proteinl'?' are additional, recently identified, signaling systems that mediate inflammatory signals independent of the TLRs and may play a pathogenic role in the initiation of the septic process. The cholinergic antiinflammatory system is a well-characterized vagally transmitted mechanism by which the nervous system is able to directly modulate host macrophage inflammatory signals via a nicotinic receptor-mediated process.l'" This neuronal-immune communication system may also prove to be amenable to therapeutic modulation in the care of septic patients.

Fully developed septic shock is obvious to the clinician, yet the early phases of severe sepsis and even septic shock may be quite subtle even to experienced clinicians. Early symptoms include confusion, apprehension, or decreased sensorium. Sudden and unexplained dyspnea (respiratory alkalosis) is a frequent early event, and it is often missed or attributed to other causes (congestive heart failure, anemia, pulmonary embolus, bronchial plugging, etc.). Fever is usually, but not invariably, present. Hypothermia in fact is a more specific and reliable finding; its presence portends an unfavorable prognosis. An unexplained decrease in urinary output, sudden onset of cholestatic jaundice, unexplained metabolic acidosis, excessive bleeding at venipuncture sites, or even sudden unexplained hypotension may be the presenting finding in septic shock. Clinicians need to recognize these early signs and symptoms since successful outcomes from severe sepsis/septic shock depend on early recognition and rapid intervention. ' Myriad clinical, laboratory, and hemodynamic abnormalities are recognized in septic shock (Table 15 .5). There is no single clinical or laboratory test that is pathognomonic of septic shock; therefore, the clinical diagnosis of sepsis remains a challenging problem. 1 Blood cultures need not be positive (and reveal no pathogen in about two-thirds of septic patients); leukocytosis or neutropenia may occur; hyperglycemia, euglycemia, or hypoglycemia may be observed; and a variety of acid-base abnormalities may occur. It is the progressive evolution of a constellation of signs and symptoms that leads to a clinical diagnosis of septic shock.

The most common hemodynamic findings in early septic shock are a high cardiac output and a low systemic vascular resistance state. Vasodilatation within the peripheral vascular system is principally related to increased NO synthesis; however, downregulation of adrenergic receptors with progressive loss of catecholamine sensitivity; excess production of the vasoactive mediators histamine, adrenomedullin, platelet-activating factor, and bradykinin; and deficiency of vasopressin all contribute to reduced vascular tone in sepsis. 84,100,104-106 The heart attempts to compensate for the loss of systemic vascular tone despite diminished myocardial performance even in the early phases of septic shock.'?' Without adequate intervention, circulating blood volume is continually lost into the interstitial spaces and intracellular locations. The heart cannot compensate indefinitely as myocardial depressant factors (NO, MIF, IL-6, TNF, other factors) are released, and cardiac performance deteriorates. Late septic shock is marked by systolic hypotension despite intense peripheral vasoconstriction and reduced cardiac index. 91, 94, 100 Septic shock may be associated with a loss of normal autoregulation within the microcirculation, with an imbalance between oxygen delivery and oxygen consumption.l'" A supply-dependent dysoxia may occur, and cytopathic hypoxia'" from diminished oxygen utilization may develop as well. Attempts to enhance oxygen delivery in sepsis to supranormal levels have not improved outcomes.v'?" but a controlled clinical trial of early goal-directed resuscitation found rapid restoration of tissue perfusion and oxygen delivery remains a critically important target in sepsis therapy. 110 Experimental Diagnostic Methods and Biomarkers for Sepsis f Since timely intervention is essential for successful outcomes in severe sepsis/septic shock, a concerted effort has been undertaken to improve the early diagnostic tools available to detect sepsis. Improved blood culture methods or measurement of plasma endotoxin levels may have diagnostic utility.'!' Circulating levels of bacterial superantigens can be detected in selected patients with toxic shock syndrome.l" Interleukin-6 has been considered an indicator of cytokine activation as its synthesis is induced by TNF-a and IL-l (3. Patients with elevated IL-6 levels appear to respond favorably to anticytokine therapies.!" In several studies,113-115 elevations of IL-6 or failure of IL-6 levels to decline over time have been associated with poor outcome. Unfortunately, the variability and lack of specificity or IL-6 measurement limits its reliability as a diagnostic method for septic shock. 

Low mixed venous O 2 indicates inadequate O 2 delivery to tissues in sepsis Cardiac index elevated in early septic shock; may be depressed in late septic shock Volume resuscitation should continue until return of normal MAP or PAWP reaches l2-lSmmHg SVR characteristically low in early septic shock secondary to peripheral vasodilation Goal of treatment is to provide sufficient D0 2 to maintain adequate mixed venous O 2 saturation Poor prognostic factor in sepsis; increased bleeding risk; thrombocytopenia may be accompanied by DIC Acute stress response (hyperglycemia), inhibition of hepatic gluconeogenesis (hypoglycemia) Coagulopathyoften seen with systemic endotoxin release; coagulation activation is almost uniform in sepsis but clinically overt DIC is uncommon Hypermetabolism, hypoperfusion of tissues, inhibition of pyruvate dehydrogenase Acute-phase proteins and products of immune cells, variable levels, sensitive but not specific indicators Measurements of O 2 content and mixed venous O 2 saturation useful in management to ensure adequate tissue oxygenation and fluid resusci tation aPTT, activated partial thromboplastin time; AT, antithrombin; DIC, disseminated intravascular coagulation; FDP, fibrin degradation products; IL, interleukin, PC, protein C; PT, prothrombin time.

Procalcitonin (PCT) is the propeptide of calcitonin, and under pathological conditions of systemic inflammation PCT is produced in abundant amounts by a variety of tissues. A specific protease cleaves procalcitonin into calcitonin, katacalcin, and an amino-terminal peptide.l" Procalcitonin has many favorable attributes as a potential marker for sepsis. It has a long half-life (approximately 24h) and will increase from undetectable levels to greater than 100ng/ml in severe sepsis/septic shock. Higher levels are associated with more severe systemic infection. II? The diagnostic and therapeutic value of PCT measurement needs to be tested in large clinical trials to determine its ultimate clinical applicability.!" The usefulness of plasma C-reactive protein, clotting factors, platelet counts, and plasma lactate levels are listed in Table  15 .5. 62 It is anticipated that progress in real-time functional genomics and proteomics in the near future will greatly aid the early recognition of incipient sepsis in patients, although the level of complexity and heterogeneity in host responses remain major, unsolved challenges in this field of medical informatics. 52, 53 Organ Dysfunction in Sepsis One of the most remarkable and characteristic findings in sepsis is the development of organ injury remote from the initial site of infection. The development of one or more organ dysfunctions at the onset of severe sepsis, or over the course of sepsis, is a poor prognostic factor and major determinant of outcome (Table 15.6 ).3,15 The diffuse endothelial injury, proapoptotic signals, immune dysregulation, and coagulopathy induced from septic shock conspire in concert to produce organ dysfunction distant from the original site of infection. It is generally assumed that the activation signals in the pathogenesis of multiorgan injury derive from plasma factors (e.g., proinflammatory cytokines, complement, phospholipid mediators),67 but cellular signals from circulating blood components/" or neuroendocrine signals may also contribute to remote organ iniury.!" Inadequate blood supply to vital tissues likely contributes to organ dysfunction. The failure of the microcirculation to maintain tissue viability is related to hypoperfusion, redistribution of blood flow within vascular beds, functional arteriovenous shunting, obstruction ofblood flow from microthrombi, platelet or white blood cell aggregates, or abnormal deformability of red blood cells. Direct endothelial injury from NO, reactive oxygen and nitrogen intermediates, proinflammatory cytokines, activated cytotoxic T cells and NK cells, and inducers of apoptosis may directly damage endothelial surfaces. 59, 72, 105 Acute lung injury occurs as a result of damage to the pulmonary vascular circulation and the alveolar-capillary membranes. The acute respiratory distress syndrome (ARDS) remains a major cause of morbidity and mortality in septic shock." Avoidance of barotrauma and volutrauma, avoidance of oxidant injury, maintenance of functional alveolar capillary units through position change (prone position), judicious Adherence and extravasation and delayed apoptosis of neutrophils, selective loss of B cells, CD4+T cells, and follicular dendritic cells Increased muscle catabolism, progressive loss of somatic muscle tissue Cerebral edema, micro thrombi Altered calcium influx, interstitial edema, myocardial hibernation Exudation of fluid into the alveolar spaces, neutrophil plugging, hyaline membrane formation Hypoperfusion, focal ischemia, micro thrombi Focal or diffuse hemorrhage, ischemic necrosis of adrenals, increased vascular sensi tivity to vasopressin Zonal necrosis, acalculous cholecystitis Diffuse interstitial edema, breaks in the epithelial membrane integrity, mucosal necrosis fluid management, and semirecumbent body positioning all reduce progressive lung damage in ventilated patients.!" The ARDS clinical trials network study confirmed the value of low stretch tidal volume settings (6mljkg) over more conventional high tidal volume settings (12mljkg).120 Low tidal volume ventilation should be utilized whenever feasible to minimize further acute lung injury in a ventilated patient. Epidemiologic studies have conclusively demonstrated that even multiple organ dysfunction from sepsis is potentially amenable to treatment if instituted rapidly and skillfully in ICUs. 3 

There are four immediate objectives in the initial management of septic shock: (1) early recognition; (2) reestablishment of tissue perfusion and arterial blood pressure by early resuscitation; (3) optimal supportive care of organ dysfunction; and (4) appropriate intervention to eradicate the causative septic focus. The 2004 surviving sepsis campaign treatment guidelines provide a useful, up-to-date, and evidence-based review of the standard treatment of sepsis.' They rank the level of evidence to support treatment decisions as follows: grade A, supported by at least two large, randomized trials; grade B, one large randomized trial; grade C, supported by smaller randomized or nonrandomized trials; grade D, supported by nonrandomized trials; or grade E, nonrandomized clinical data and expert opinion. There is considerable agreement regarding basic resuscitation strategies and organ support maneuvers. There is general consensus about the need to remove the septic focus as soon as possible and initiate appropriate antimicrobial agents against the causative pathogens. Treatment options vary considerably with respect to the timing of interventions, amount and type of fluid administration, value of specific vasopressor therapies, and advisability of treatment interventions of unclear or experi-mental clinical utility. Areas of general agreement and options lacking uniform consensus are addressed in this section.

Fluid resuscitation is an essential first step in the management of septic shock. The loss of vasomotor tone and increased vascular permeability necessitate immediate correction to maintain tissue perfusion and provide adequate circulating blood volume. Debate has raged for decades over the relative merits of colloids versus crystalloid fluids. The lack of clear evidence of benefit of colloid agents (e.g., albumin, dextran, and plasma expanders) and their high cost have favored the use of saline solutions for volume expansion.P'{" A large, controlled clinical trial was undertaken recently in Australia and New Zealand in an effort to finally settle this debate.P" In a comparative study of nearly 7000 critically ill patients randomized to saline versus 40/0 albumin, the 28 day all-cause mortality was virtually identical (relative risk 0.99, P = n.s.). This would seem to have settled the debate except that a subgroup analysis of over 1200 septic patients suggested an improved outcome in the albumin group (30.7% vs. 35.3% saline group, P = .06). Current consensus opinion still favors cystalloid solutions.'

The optimal amount of fluid therapy for patients in septic shock remains unclear, but a study by Rivers and colleagues'P supported the notion that early, aggressive, and goal-directed resuscitation fluids should be widely adopted as the standard approach to early fluid administration. They recommended a treatment regimen aimed at resolving lactic acidemia, recovery of mean arterial blood pressure over 65 mmHg, and return of central venous pressure above 8 mmHg and mixed venous oxygen saturation above 700/0 within 6h of initial presentation (grade B evidence).

A delicate balance is required between maintenance of tissue perfusion and prevention of fluid overload, with its attendant risk of lung injury. Decreased myocardial performance in sepsis may necessitate a higher filling pressure for adequate cardiac output; however, exudation of fluids into the alveolar space in lung tissue and into the interstitium in other vital organs continues to be a major problem. Maintenance of a pulmonary arterial occlusion pressure of approximately l2mmHg is considered a reasonable starting point for those patients with a hemodynamic monitor in place (grade B).3

When patients fail to recover hemodynamic stability with fluid resuscitation alone, vasopressor agents are indicated to reestablish systemic arterial blood pressure. Dopamine has been the vasopressor agent of choice for several decades based on its presumed salutary effects on renal vasodilatation and its modest inotropic effects.P' The actual clinical value of dopamine compared with other vasopressor agents has been brought into question. Dopamine has complex effects as this catecholamine has its own receptors (Dl and D2 dopaminergic receptors) and variable affinities for a-and~-adrenergic receptors. The net effect of dopamine depends on many variables, including the receptor density in specific vascular beds, blood volume, and the rate of administration of drug dose used. Higher doses of dopamine increase the systemic vascular resistance by its effects on a-adrenergic receptors in the peripheral circulation. Dopamine may have adverse effects on splanchnic blood flow,3,124 and there is no evidence in controlled trials that dopamine has any meaningful renal perfusion benefits.' The use of dopamine as a "renal-sparing" agent is no longer justified (grade B). 3, 125 Norepinephrine is a potent vasoconstrictor that is used more frequently to treat the hemodynamic effects of septic shock. Earlier concerns regarding adverse consequences of norepinephrine on renal blood flow may have been overstated; studies suggested that norepinephrine may actually increase urine output and creatinine clearance in septic patients.!" Norepinephrine may rapidly restore perfusion pressure within the glomerulus and result in improved glomerular filtration in patients with adequate fluid resuscitation. Current consensus opinion recommends either dopamine or norepinephrine as the initial vasopressor to correct hypotension in septic shock (grade D). 3 Vasopressin is a potent vasopressor in refractory sepsis. Endogenous vasopressin levels rapidly fall in sepsis, and vasopressin has its own vascular receptors that are distinct from adrenergic receptors and often upregulated in sepsis.!" There is concern about diminished splanchnic blood flow with higher doses of vasopressin, and myocardial ischemia may occur at infusion rates above 0.04 unit/min. Vasopressin may be considered in refractory shock, but it has not replaced dopamine or norepinephrine for first-line vasopressors in septic shock (grade E). 3 Dobutamine, a~-agonist, may improve cardiac output and oxygen delivery in some patients in septic shock with persistently low cardiac output. Dobutamine may cause peripheral vasodilatation in septic patients, and it increases myocardial oxygen consumption by its inotropic effects. ' Another approach to improved tissue oxygen delivery is by use of vasodilators to open up poorly perfused capillary beds in patients with septic shock. Spronk et al. 128 reported the use of nitroglycerin therapy in patients following intravascular volume resuscitation. Using an optical device to measure microcirculatory flow (orthogonal polarization spec-tral imaging), they were able to show improved microvascular flow rates in septic patients who received adequate fluid repletion. This is an appealing strategy but must be considered experimental at present until further clinical trials are completed using this approach.

Numerous techniques are under study to clinically measure tissue oxygenation by gastric tonometry, hepatic venous oxygen measurements, direct tissue oxygen probes, and microcirculatory units for visualized capillary blood flow." The practical value of these measurements in the clinical management of sepsis has yet to be demonstrated.

The relative merits of blood transfusion or erythropoietin necessity to improve the oxygen-carrying capacity of blood remains a subject of considerable debate. 129,130 It has been demonstrated that humans are remarkably resistant to adverse effects from isovolumetric anemia.131 Banked, stored red blood cells are less deformable, less efficient at releasing their oxygen from 2,3-biphosphoglycerate-depleted hemoglobin stores, and may have immunosuppressive effects.!" Efforts to promote endogenous erythrocyte production with erythropoietin treatments have yet to be proven superior to blood transfusions.!" Further clinical trials are warranted with this treatment approach. The lower limit of transfusion threshold in septic shock has not been defined, but it appears to be considerably lower than the traditional transfusion threshold of less than IOg/dl, Studies of patients in the leu setting indicated that a conservative transfusion policy at 7-9 g/dl may be preferable'F (grade B recommendation).

Expert management of acute renal failure, renal replacement therapy, ARDS treatment, hepatic decompensation, acid-base disturbances, and disordered hemodynamics are of critical importance in the management of sepsis. These topics have been addressed in recent treatment guidelines" and are dealt with extensively in other chapters in this book. Nutritional support in the critically ill patient has changed radically over the past two decades. Reliance on total parenteral nutrition has given way to early and extensive use of enteral hyperalimentation. Enteral feeding of septic patients has been shown to benefit enterocyte function, help maintain the intestinal permeability barrier, and prevent gut-derived endotoxin and cytokine generation.!" Nutritional supplementation with glutamine, arginine, and omega-3 fatty acids has experimental support and remains an active area of research, yet convincing clinical efficacy studies are not yet available. 134 Fever is frequently concomitant to severe infection and is generally considered advantageous to the host.F" Experimental animals with peritonitis clear infection and recover more rapidly when allowed to develop fever compared to a control group with externally controlled normothermia.l" Heatshock proteins function as molecular chaperones and prevent protein denaturation during cellular stress. Heat-shock protein induction may actually improve outcomes in experimental endotoxin challenge.!" Cooling blankets to lower body temperature should be avoided as they are uncomfortable for patients and generally ineffective unless true hyperthermia is present. 138 Antibiotics are considered an adjuvant therapy to source control with drainage, relief of obstruction, or removal of the Third-or fourth-generation cephalosporins or extendedspectrum penicillins or~-lactam-~-lactamase inhibitor with metronidazole or clindamycin; or carbapenem ± an aminoglycoside (alternative: fluoroquinolone) Extended-spectrum penicillin or third-or fourth-generation cephalosporin or carbapenem or~-lactam-~-lactamase inhibitor; add clindamycin if streptococcal or staphylococcal toxic shock suspected Third-generation cephalosporin with a macrolide (alternative: fluoroquinolones) Third-/fourth-generation cephalosporins, extendedspectrum penicillins ± an aminoglycoside (alternatives: fluoroquinolones, carbapenems,~-lactam-~-lactamase inhibitor) Extended-spectrum~-lactam agent (third-generation cephalosporin or extended-spectrum penicillin); or a fluoroquinolone (add ampicillin or vancomycin if enterococci are present, linezolid if vancomycin-resistant enterococci) Extended-spectrum penicillin ± an aminoglycoside or fluoroquinolone (add metronidazole if hepatic abscess present) Extended-spectrum~-lactam agent ± an aminoglycoside or quinolone (add vancomycin if evidence of gram-positive infection) aAssuming no drug allergies an empiric choice should be based on local antibiotic resistance patterns. offending focus of infection when possible (grade E recommendatiorr']. Suggested empiric choices of antimicrobial agents are listed in Table 15 .7. In septic shock, combinations of bactericidal antimicrobial agents are generally given on an empirical basis, yet monotherapy with an effective broad-spectrum~-lactam or fluoroquinolone is usually sufficient (grade D 3 ). Ineffective empiric antibiotic choices for initial therapy for sepsis have adverse consequences.F'<" and therefore it is preferable to ensure adequate initial therapy and then deescalate to single narrow-spectrum agents after the causative organism is identified. 140 Euglycemia, Steroids, and Recombinant Humañ ctivated Protein c:

Other important supportive management techniques in sepsis are tight regulation of blood glucose levels and use of stress dose glucocorticoids in the presence of relative adrenal insufficiency. Hyperglycemia can increase procoagulant activity on endothelial surfaces and may induce excess apoptosis.!" Van den Berghe et a1. 142 demonstrated improved survival, shorter ICU stays, and less bacteremia in some surgical population with strict control over blood sugar (target was continuous euglycemia) versus conventional care in a cardiovascular ICU setting. It is recommended that blood sugar levels be kept under 150mg/dl if at all feasible in septic patients (grade D 3 ) .

Annane and coworkers'f reported significant survival benefits in a study of 299 patients with vasopressor-dependent septic shock; the study used hydrocortisone (50mg every 6h for 7 days) and fludrocortisone (50Jlg/day for 7 days). This treatment strategy is based on the frequent occurrence of relative adrenal insufficiency in patients with septic shock. I44 , 145 The low-dose corticosteroid therapy was only effective in those patients with evidence of inadequate adrenal responses to a short corticotropin test.l" Stress dose steroids should be discontinued if normal cortisol levels and corticotropin responses are found (grade C).

The results of the recombinant human activated protein C trial (drotrecogin alfa activated) represent the first successful phase III international trial in severe sepsis." It is given as a continuous infusion at 24 flg/kg/h for 4 days. Since the molecule is an endogenous anticoagulant, the major side effect of treatment is bleeding. Carefully selected patients benefit from this treatment regardless of the type of infecting microorganism that caused sepsis" (grade B recommendatiorr'],

The wealth of new discoveries into the central molecular events that underlie sepsis and the unmet medical need for improved therapies for sepsis have created an ongoing impetus to develop innovative treatments for sepsis. Some of those experimental strategies that are in clinical trials or nearing clinical investigation are listed in Table 15 .8 along with their presumed mechanism of action. Translational research has already brought novel treatments such as stress dose steroids, low stretch mechanical ventilation, enteral nutrition, and activated protein C into clinical use. It is anticipated that the genomic era will speed the development of innovations into clinical practice. Much-needed research continues on preventive strategies, improved diagnostics, and more effective treatment interventions to improve the outlook for this evergrowing population of septic patients. 43 ; other studies are ongoing (recent unpublished report of no benefit for one trial).

International sepsis survey: A study of doctor's knowledge and perception about sepsis

SCCM/ESICM/ ACCP /ATS/SIS International Sepsis Definitions Conference

Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

Epidemiology of sepsis in the United States from 1979-2000

Epidemiology of sepsis and infection in ICU patients from international multicenter cohort study

Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of the Sociedad Espanola de Medicina Intensiva Unidades Coronarias (SEMIUC)

Has the mortality of septic shock changed with time?

Epidemiology of sepsis syndrome in eight academic medical centers

EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units

Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis

Neurological complications of sepsis: critical illness polyneuropathy and myopathy

The costs of septic syndromes in the intensive care unit and the influence of hospital-acquired sepsis

Gram-negative bacteremia. m. Reassessment of etiology, epidemiology and ecology in 612 patients

Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients

Systemic host response to sepsis based upon the infectious microorganism and effects of drotrecogin alfa activated

Diagnosis of infection in sepsis: an evidence-based review

Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

Infection associated with asplenia: risks, mechanisms and prevention

Genetic and environmental influences on premature death in adult adoptees

A mutation in the interferon-y receptor gene and susceptibility to mycobacterial infection

Science review: key inflammatory and stress pathways in critical illness

Relevance of mutations in the TLR4-receptor in patients with gram-negative septic shock

Association between a genomic polymorphism with the CD14 locus and septic shock susceptibility and mortality rate

Human toll-like receptor 4 mutations but not CD 14 polymorphisms are associated with increased risk of gram-negative infections

Association of TNF2, a TNFa promoter polymorphism, with septic shock susceptibility and mortality

An interleukin-l genotype is associated with fatal outcome of meningococcal disease

Variation in the tumor necrosis factor-a gene promoter region may be associated with death from meningococcal disease

et ale Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility

The G~a single nucleotide polymorphism at the -308 position in the tumor necrosis factoralpha promoter increases the risk for severe sepsis

A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome patients with severe sepsis

Effect of the interleukin-6 promoter polymorphism (-174G/C) on the incidence and outcome of sepsis

Gram-positive organisms in sepsis

Endotoxemia in human septic shock

Bacterial endotoxin: molecular mechanisms of structure to activity and function

A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR)2 but not via TLR4/MD2

Innate immunity

LPS-binding proteins and receptors

CD14 is a pattern recognition receptor

Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability increasing protein and cefamandole in treatment of rabbit gram-negative sepsis

Recombinant bactericidal/permeability-increasing protein (rBPI 2 das adjunctive treatment for children with severe meningococcal sepsis: a randomised trial

Defective signaling in C3H/ HeJ and C57BL/I0ScCr mice: mutations in Tlr4 gene

Differential roles of TLR2 and TLR4 in recognition of gram-negative and grampositive bacterial cell wall components

et ale Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

The human toll-like receptors as a therapeutic target

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

A toll-like receptor that prevents infection by uropathogenic bacteria

et ale Complement activation in patients with sepsis is in part mediated by C-reactive protein

MBL genotype and risk of invasive pneumococcal disease: a case-control study

CD14, new aspects of ligand and signal diversity

Human macrophage activation programs induced by bacterial pathogens

Diehn M, et ale Stereotyped and specific gene expression programs in human innate immune responses to bacteria

The biology of toll-like receptors

A toll-like receptor recognizes bacterial DNA

Recognition of double stranded RNA and activation of NF1d3 by Toll-like receptor 3

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

Selective expansion of T cells expressing Vb2 in toxic shock syndrome

The pathology and treatment of sepsis

Immunoregulatory mechanisms of T-cell-dependent shock induced by bacterial superantigen in mice

Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock

Shock and tissue injury inducedby recombinanthuman cachectin

Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans

Initial evaluation of human recombinant interleukin-l receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

Anticytokine strategies in the treatment of the systemic inflammatory response syndrome

Chemokines: chemotactic cytokines that mediate inflammation

LPS-inducible responses in severe combined immunodeficiency (SCID) mice

Regulation of the interleukin (IL)-12Rb2 subunit expression in developing T helper 1 (Thl) and Th2 cells

Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery

Apototic cell death in patients with sepsis, shock and multiple organ dysfunction

Interleukin-l0 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis

Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways

Neutralization of IL-I0 increases survival in a murine model of Klebsiella pneumonia

Nitric oxide and macrophage function

Prospective: targeting nitric oxide in the adjuvant therapy of sepsis in meningitis

phosphate) ribose polymerase activation as a cause of metabolic dysfunction in critical illness

Hack CEo Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

Rotstein ODe Role of the coagulation system in the local and systemic inflammatory response

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

Time course of hemostatic abnormalities in sepsis and its relation to outcome

Thrombin receptor function and cardiovascular disease

Disseminated intravascular coagulation

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

Safety and efficacy of activated protein C for severe sepsis

High-dose antithrombin III in severe sepsis. A randomized controlled trial

Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis

Heparin therapy in bacterial septicemia

The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/ endothelial cell interaction and microvascular perfusion failure

Treating patients with severe sepsis

Why do animal models (sometimes) fail to mimic human sepsis?

Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4)

Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor

Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway

Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis

Mini-review: the nuclear protein HMGBI as a proinflammatory mediator

Extracellular role of HMGBI in inflammation and sepsis

Reversing established sepsis with antagonists of endogenous high-mobility group box 1

Novel strategies for the treatment of septic shock

TREM-l amplifies inflammation and is crucial mediator of septic shock

An essential role for NOD-l in host recognition of peptidoglycan containing diaminopimelic acid

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock

The pathogenesis of vasodilatory shock

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

Physiologic patterns in surviving and non-surviving shock patients

Cytotoxic hypoxia in sepsis

Elevation of systemic oxygen delivery in the treatment of critically ill patients

Early goal-directed therapy in the treatment of severe sepsis and septic shock

Diagnostic and prognostic implications of endotoxemia in critical illness: results of the Medic trial

Detection of circulating bacterial superantigen and lymphotoxin alpha in patients with streptococcal toxic-shock syndrome

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebocontrolled, dose-ranging study

Cytokine serum levels during severe sepsis in humans: IL-6 as a marker of severity

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial

Procalcitonin: a new indicator of systemic response to severe infections

Procalcitonin as a marker for the early diagnosis of neonatal infection

Cytokines, nitrite/ nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentration: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia

Supine body position as a risk factor for nosocominal pneumonia in mechanically ventilated patients: a randomised trial

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Human albumin administration in critically ill patients: systematic review of randomized controlled trials

Patient survival after human albumin administration

A comparison of albumin and saline for fluid resuscitation in the intensive care unit

Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?

Use of dopamine in acute renal failure: a meta-analysis

Renal effects of norepinephrine used to treat septic shock patients

Physiology of vasopressin relevant to management of septic shock

Nitroglycerin in septic shock after intravascular fluid resuscitation

Blood transfusion in elderly patients with acute myocardial infarction

Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial

Human cardiovascular and metabolic response to acute, severe isovolemic anemia

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care

Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma

Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter prospective, randomized, clinical trial

The adaptive value of fever

Febrile core temperature is essential for optimal host defense in bacterial peritonitis

Heat stress after injection of LPS in rats decreases mortality

Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit

Optimizing antibiotic therapy in the intensive care unit setting

The influence of inadequate antimicrobial treatment of blood stream infection on patient outcomes in the ICU setting

Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men

Intensive insulin therapy in critically ill patients

Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone

Immunologic and hemodynamic effects of "low dose" hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled crossover study